Clinical Trial Update: A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003) [Phase 1]

View source ↗

Summary

A Phase 1 single-dose trial of MK-8351 in an asthma lung allergen challenge was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• MK-8351

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Asthma | Phase 1 | Status: WITHDRAWN